Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Abstract Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the mechanism-of-action of bortezomib in br...

詳細記述

書誌詳細

主要な著者:	Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Portfolio 2024-08-01
シリーズ:	Scientific Reports
主題:	Drug repurposing Proteasome inhibitor Bortezomib Gene expression profiling Mutation profiling Cancer
オンライン･アクセス:	https://doi.org/10.1038/s41598-024-62339-x
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!